A new ICT-based device (RHEO-01) for fast point-of-care analysis of acute ischemic stroke and other emergency situations.

Información del proyecto

ERYTHROAG

Identificador del acuerdo de subvención: 735480

DOI

10.3030/735480

Proyecto cerrado

Fecha de la firma de la CE 24 Julio 2016

Fecha de inicio 1 Agosto 2016

Fecha de finalización 31 Enero 2017

Financiado con arreglo a

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

RHEOFAST
France

Periodic Reporting for period 1 - ERYTHROAG (A new ICT-based device (RHEO-01) for fast point-of-care analysis of acute ischemic stroke and other emergency situations.)

Período documentado: 2016-08-01 hasta 2017-01-31

Resumen del contexto y de los objetivos generales del proyecto

Stroke is the most frequent cause of long-term disability in Europe, mainly in middle-aged and elderly people. Stroke imposes a huge health care economic burden: >5B€/year in France.
RHEOFAST's RHEO-01 is a disruptive ICT-based smart decision support tool for medical emergency management. This tool will provide the physician with personalized patient’s health status assessment in a few minutes. It has three components which have to be evaluated:
- Fast, easily and highly reliable measurement of erythrocyte aggregation kinetics (EAK), a new biomarker of inflammation, and its medical relevance.
- Remote smart data processing and comparison with a reference dataset.
- Physician-friendly results for fast decision support.
This tool can be used in emergency vehicles and at the point of care.
In this phase 1, we evaluated whether RHEO-01 concept is feasible from a technical and a financial point of view and whether acute stroke management is the best indication for RHEO-01

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

With the most extensive clinical programme ever conducted and evaluating erythrocyte aggregation in clinical setting (1,300 measurements in 500 subjects) we were able to build and test a high-accuracy measurement of EAK, as well as to define the technical requirements for the smart data processing of EAK information. Our technique is well protected (pending PCT patents). Contrary to our initial hypothesis, both our clinical trials and our market analysis showed that the most promising indication for our product may likely be the management of acute chest pain suspected of heart attack. As for stroke management, timesaving is critical for improving the management and treatment of victims of heart attacks.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

Cardiovascular disease remains the leading cause of death in Europe (42%), including coronary heart disease (20%) and stroke (10%). CVD is also the leading cause of years lived with disabilities in Europe.
By providing key, fast information for the appropriate orientation of patients suspected of heart attack, RHEO-01 might be able to improve patients survival, limit myocardial infarct size and, thereby chronic heart failure in these patients.

RHEOFAST